Arnd Kaltofen-Ehmann

Omthera Pharmaceuticals, Inc. operates as pharmaceuticals company which focuses on the clinical development of new therapies for dyslipidemia. The company was founded by Jerry Wisler and Michael Davidson in 2008 and is headquartered in Princeton, NJ.

Part of CRA Holdings LLC, Chicago Center for Clinical Research is an American company that provides clinical research services. The company was founded by Michael H. Davidson.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

The American College of Chest Physicians is a leading organization in clinical chest medicine, with over 19,000 members providing patient care in pulmonary, critical care, and sleep medicine in more than 100 countries worldwide. The non-profit company is based in Northbrook, IL. The organization offers access to clinical guidelines, new research, and clinical topic collections through their website, as well as opportunities for members to become more involved in the chest medicine community. The organization's mission is to promote the prevention, diagnosis, and treatment of chest diseases through education, communication, and research. Robert A. Musacchio has been the CEO of the company since 2015.

American College of Cardiology Foundation provides cardiovascular education services. Its services include cardiac surgery, chronic angine, diabetes, geriatric cardiology and heart failure and cardiomyopathies. The company was founded by Franz Groedel, Robert P. Glover and Bruno Kisc in 1949 and is headquartered in Washington, DC.

Cerenis Therapeutics, Inc. discovers, develops and commercializes drugs for the treatment of cardiovascular and metabolic diseases. It focuses on discovery, development, and commercialization of HDL therapies. Cerenis Therapeutics is located in Ann Arbor, MI.

Abcentra, Inc. is an American clinical-stage biopharmaceutical company that specializes in developing novel antibody therapies for inflammatory diseases, with a particular focus on cardiovascular disease. The private company's patented technology allows for the targeting of oxidized lipoproteins and associated inflammatory responses. Abcentra's pipeline focuses on patient populations with high-risk of cardiometabolic complications that are exacerbated by chronic inflammation, including patients with inflammatory diseases and patients with residual inflammation. The company's lead compound, orticumab, is a novel monoclonal antibody that blocks inflammation from oxidized low-density lipoprotein and is slated to begin a phase 2 study later this year. Kevin B. Bacon has been the CEO of the company since 2020.

Burckhardt Compression AG manufactures reciprocating compressor technologies. It offers compressor solutions to the upstream oil and gas, gas transport and storage, refinery, petrochemical and chemical and industrial gas sectors. The firm’s services include valve reconditioning, spare parts logistics, field service, technical support, component repair, revamps and upgrades, trainings, and condition monitoring and diagnostics. The company was founded in 1844 and is headquartered in Winterthur, Switzerland.

Inamed GmbH engages in the development of drug inhalation systems and therapies. Its products include organic fiber and fiber products; nondiagnostic biological products; medical instruments; surgical appliances; and supplies. The company was founded by Thomas Meyer and Gerhard Scheuch in 1998 and is headquartered in Gauting, Germany.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

HealthUp Sp zoo develops MySpiroo -a mobile spirometer, which is a handheld, portable, wireless, smartphone connected medical device. The company was founded on August 19, 2014 and is headquartered in Warsaw, Poland.

Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

Jocasta Neuroscience, Inc. provides biological products development services. The company is based in New Castle, DE.

NanoPhoria Srl is an Italian company that operates as a non-viral drug delivery platform. The company is based in Milan, Italy. The company was founded by Daniele Catalucci, Michele Iafisco, Alessio Alogna, Claudio de Luca. Claudio de Luca has been the CEO since incorporation.

Trofi Nutritionals, Inc. is a private company located in the US that is focused on advancing personal health management through next-generation nutritional wellness solutions. The American company works with partners to translate functional compound discoveries into nutritional solutions.

SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

The National Lipid Association aims to improve the practice of lipid management in clinical medicine. The non-profit company is based in Jacksonville, FL and has subsidiaries in the United States. The organization's mission is to enhance lipid management in clinical medicine, and its goals are consistent with this mission statement.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.